Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PTN up 20% Phase 3 results of dry eye drug imminent and its still underpriced at 50 million valuation
PTN hit $3 -Phase 3 results imminent (expected in Q4)
PTN - P3 results imminent stock looks like about to breakout
PTN $2.60 Phase 3 data IMMINENT for their dry eye treatment , market cap only 36 million this low float will explode IF results are positive
Presentation
https://palatin.com/wp-content/uploads/2023/12/PTN_Website_Corp_Presentation_December_2023_120423.pdf
PTN $2.50 - Phase 3 results of dry eye treatmnent is imminent expected before year end .. the dry eye disease is a $3+ billion market so if the results are positive then this low floater which is valued at only $34 million is going to explode .
https://palatin.com/pipeline/
VNDA $3.80 has HUGE cash of $8.50 per share ,its profitable and has 3 more Drugs awaiting FDA approval with FDA decision in March ,April and September . This stock is a monster opportunity guys with all the potential upcoming FDA approvals .
Presentation
https://www.vandapharma.com/pdfs/vanda_corporate_presentation_nov_23.pdf
VNDA $3.93 has 3x FDA Decisions within 9 months for Insomnia ,Bipolar and gastroparesis treatments the first pdufa date is in early March next one in April and in September . VNDA is trading massive under cash balance .
VNDA $3.80 has HUGE cash of $8.50 per share ,its profitable and has 3 more Drugs awaiting FDA approval with FDA decision in March ,April and September . This stock is a monster opportunity guys with all the potential upcoming FDA approvals .
Presentation
https://www.vandapharma.com/pdfs/vanda_corporate_presentation_nov_23.pdf
VNDA $3.80 has HUGE cash of $8.50 per share ,its profitable and has 3 more Drugs awaiting FDA approval with FDA decision in March ,April and September . This stock is a monster opportunity guys with all the potential upcoming FDA approvals .
Presentation
https://www.vandapharma.com/pdfs/vanda_corporate_presentation_nov_23.pdf
VNDA $3.80 has HUGE cash of $8.50 per share ,its profitable and has 3 more Drugs awaiting FDA approval with FDA decision in March ,April and September . This stock is a monster opportunity guys with all the potential upcoming FDA approvals .
Presentation
https://www.vandapharma.com/pdfs/vanda_corporate_presentation_nov_23.pdf
EYEN $1.65 FDA Decision in March and has 3 Phase 3 Programs each drug targeting multi billion dollar market while market cap is at only 73 million
MAIA -MC $18 m - has blockbuster cancer drug with potential accelerated approval in 2 yeear , this is another cheap biotech with massive upside potential
Summary
https://d1io3yog0oux5.cloudfront.net/_f76eccf903f2a26f3902e8f81512ee64/maiabiotech/db/2216/20714/pdf/2023-10-19+MAIA+Biotechnology+-+TwoPager.pdf
ANVS $6.50 -Alzheimer & Parkinson trials both in Phase 3 with results expected in Q1 , market cap only 65 million .. this could be a 10 bagger on positive results
Annovis looks to advance pivotal Alzheimer’s and Parkinson’s drug studies
https://www.pharmaceutical-technology.com/news/annovis-looks-to-advance-pivotal-alzheimers-and-parkinsons-drug-studies/
Annovis Bio is working to progress its lead oral drug for Alzheimer’s disease (AD) and Parkinson’s disease (PD) studies as two trials evaluating the therapy’s potential reach the tail-end of their recruiting goals, CEO Maria Maccecchini, PhD, told Pharmaceutical Technology.
Data from both trials is expected in the first half of 2024.
CLNN $0.45 -has Blockbuster drug (ALS treatment) with potential accelerated FDA approval by next year . stock trading near cash and there was some big insider buying at higher price in last few months see link below . they will meet with FDA in the coming days to talk about a accelerated NDA submission if FDA gives green light then the stock likely will rally .
insider buying
http://openinsider.com/search?q=clnn
TFFP 0.29 up 32% important data readout could hit the wire any day now ...if positive this one could go over $1
Company remains on track to report initial data from TFF VORI and TFF TAC Phase 2 trials by the end of 2023
VNDA $3.40 has MASSIVE cash of $8.50 per share and 2x FDA Decision in 1H 2024 ......This one is terrible underpriced
Market Cap $200 million while Cash ist at $490 million
https://vandapharmaceuticalsinc.gcs-web.com/node/15601/pdf
The sNDA for HETLIOZ® in insomnia was accepted for filing by the FDA with a PDUFA target action date of March 4,
2024
The supplemental New Drug Application (sNDA) for Fanapt® in bipolar I disorder in adults was accepted for filing by the
U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of April 2,
2024.
FBIO up 28% --FDA decision for cancer drug in early january market cap still around 25 million
FBIO $1.45 FDA decision in 5 weeks (cancer drug) market cap at unbelievable $22 million
FBIO $1.35 -MC $18 m -FDA Decision on January 3 (cancer treatment) and NDA submission for rosacea treatment expected before year end .super cheap low floater with nice upside
https://finance.yahoo.com/news/fortress-biotech-reports-third-quarter-211000362.html
We’re looking forward to multiple significant near-term milestones, including potentially up to four New Drug Application (“NDA”) and Biologics License Application (“BLA”) submissions to the U.S. Food and Drug Administration (“FDA”) between 2023 and 2025, one of which is a NDA for DFD-29 to treat rosacea around the end of this year. We are also anticipating the PDUFA goal date of January 3, 2024, for cosibelimab, our investigational anti-PD-L1 antibody, as a treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (“cSCC”).”
FBIO $1.35 -MC $18 m -FDA Decision on January 3 (cancer treatment) and NDA submission for rosacea treatment expected before year end .super cheap low floater with nice upside
https://finance.yahoo.com/news/fortress-biotech-reports-third-quarter-211000362.html
We’re looking forward to multiple significant near-term milestones, including potentially up to four New Drug Application (“NDA”) and Biologics License Application (“BLA”) submissions to the U.S. Food and Drug Administration (“FDA”) between 2023 and 2025, one of which is a NDA for DFD-29 to treat rosacea around the end of this year. We are also anticipating the PDUFA goal date of January 3, 2024, for cosibelimab, our investigational anti-PD-L1 antibody, as a treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (“cSCC”).”
FBIO $1.35 -MC $15 m -FDA Decision on January 3 (cancer treatment) and NDA submission for rosacea treatment expected before year end .super cheap low floater with nice upside
https://finance.yahoo.com/news/fortress-biotech-reports-third-quarter-211000362.html
We’re looking forward to multiple significant near-term milestones, including potentially up to four New Drug Application (“NDA”) and Biologics License Application (“BLA”) submissions to the U.S. Food and Drug Administration (“FDA”) between 2023 and 2025, one of which is a NDA for DFD-29 to treat rosacea around the end of this year. We are also anticipating the PDUFA goal date of January 3, 2024, for cosibelimab, our investigational anti-PD-L1 antibody, as a treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (“cSCC”).”
FBIO $1.35 -MC $15 m -FDA Decision on January 3 (cancer treatment) and NDA submission for rosacea treatment expected before year end .super cheap low floater with nice upside
https://finance.yahoo.com/news/fortress-biotech-reports-third-quarter-211000362.html
We’re looking forward to multiple significant near-term milestones, including potentially up to four New Drug Application (“NDA”) and Biologics License Application (“BLA”) submissions to the U.S. Food and Drug Administration (“FDA”) between 2023 and 2025, one of which is a NDA for DFD-29 to treat rosacea around the end of this year. We are also anticipating the PDUFA goal date of January 3, 2024, for cosibelimab, our investigational anti-PD-L1 antibody, as a treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (“cSCC”).”
TFFP 0.22 may be next TPST , important data readout expected before year end
pipeline
https://tffpharma.com/programs/#pipeline
OCUP $3 -BIg Phase 3 readout imminent (in Q4) stock trading at cash level
Pipeline
https://www.ocuphire.com/product-pipeline
FBIO $2 cancer drug approval soon ..market cap $18 million which is a big joke ...another 3 NDA/BLA filings expected within 12 months
Biologics License Application for cosibelimab under review by U.S. FDA; Successful mid-cycle meeting with U.S. FDA completed; PDUFA goal date of January 3, 2024
latest presentation
https://d1io3yog0oux5.cloudfront.net/_ed50be51b6beb6fd48870d3b98dc0b4e/fortressbiotech/db/640/6031/pdf/FBIO+Corporate+Presentation+-+October+2023.+%281%29.pdf
FBIO $2 cancer drug approval soon ..market cap $18 million which is a big joke ...another 3 NDA/BLA filings expected within 12 months
FBIO $2 cancer drug approval soon ..market cap $18 million which is a big joke ...another 3 NDA/BLA filings expected within 12 months
FBIO up 22% ..FDA decision in 8 weeks ..market cap of $17 million is a mega gift
FBIO $1.70 -Cancer Drug approval in 8 weeks (PDUFA date january 3 ) market cap only 16 million
Biologics License Application for cosibelimab under review by U.S. FDA; Successful mid-cycle meeting with U.S. FDA completed; PDUFA goal date of January 3, 2024
latest presentation
https://d1io3yog0oux5.cloudfront.net/_ed50be51b6beb6fd48870d3b98dc0b4e/fortressbiotech/db/640/6031/pdf/FBIO+Corporate+Presentation+-+October+2023.+%281%29.pdf
FBIO $1.70 -Cancer Drug approval in 8 weeks (PDUFA date january 3 ) market cap only 16 million
Biologics License Application for cosibelimab under review by U.S. FDA; Successful mid-cycle meeting with U.S. FDA completed; PDUFA goal date of January 3, 2024
latest presentation
https://d1io3yog0oux5.cloudfront.net/_ed50be51b6beb6fd48870d3b98dc0b4e/fortressbiotech/db/640/6031/pdf/FBIO+Corporate+Presentation+-+October+2023.+%281%29.pdf
FBIO $1.70 -Cancer Drug approval in 8 weeks (PDUFA date january 3 ) market cap only 16 million
FBIO -MC $15 m FDA decision in 8 weeks (cancer drug) ...this low floater has multiple subsidiarys and its likely one of the cheapest biotechs out there
latest presentation
https://d1io3yog0oux5.cloudfront.net/_ed50be51b6beb6fd48870d3b98dc0b4e/fortressbiotech/db/640/6031/pdf/FBIO+Corporate+Presentation+-+October+2023.+%281%29.pdf
EYEN $1.37 about to breakout has a drug awaiting FDA approval and another 2 Drugs in Phase 3 ...super cheap at $52 million valuation
MAIA $1.85 -MC $22 m -has lung cancer drug that could be approved within 2 years ...
Investment Summary
https://d1io3yog0oux5.cloudfront.net/_28c74c59a9eef004c28b99c8bd7977cd/maiabiotech/db/2216/20714/pdf/2023-07-12+MAIA+Biotechnology+-+TwoPager.pdf